Emergent Biosolutions(EBS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

EBS Emergent Biosolutions

盘前交易 02-18 04:28:43 EST

10.70

-0.13

-1.20%

最高11.08	最低10.65	成交量35.85万
今开10.79	昨收10.83	日振幅3.97%
总市值5.62亿	流通市值5.48亿	总股本5,252万
成交额386.55万	换手率0.70%	流通股本5,126万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"EBS","market":"US","secType":"STK","nameCN":"Emergent Biosolutions","latestPrice":10.7,"timestamp":1771362000000,"preClose":10.83,"halted":0,"volume":358477,"delay":0,"changeRate":-0.01200369344413673,"floatShares":51257100,"shares":52519964,"eps":1.350708,"marketStatus":"盘前交易","change":-0.13,"latestTime":"02-18 04:28:43 EST","open":10.79,"high":11.08,"low":10.65,"amount":3865483.1221055,"amplitude":0.039705,"askPrice":12.6,"askSize":100,"bidPrice":9.15,"bidSize":100,"shortable":3,"etf":0,"ttmEps":1.350708,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1771425000000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1254456000000,"exchange":"NYSE","adjPreClose":10.7,"postHourTrading":{"tag":"盘后","latestPrice":10.7,"preClose":10.7,"latestTime":"18:22 EST","volume":7193,"amount":76960.48,"timestamp":1771370548015,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.6624913789758009,"impliedVol":1.1744,"impliedVolPercentile":0.916},"requestUrl":"/m/hq/s/EBS/tweets","defaultTab":"tweets","newsList":[{"id":"1177146443","title":"Emergent BioSolutions获FDA批准Narcan鼻喷雾多包装补充新药申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1177146443","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177146443?lang=zh_cn&edition=full","pubTime":"2026-02-13 07:00","pubTimestamp":1770937212,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已正式批准Emergent BioSolutions公司提交的Narcan®鼻喷雾多包装补充新药申请。这一审批标志着该产品在包装形式上获得重要扩展，为用药便利性和可及性带来提升。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EBS","BK4583"],"gpt_icon":0},{"id":"2605742942","title":"Emergent Biosolutions Inc.盘中异动 急速拉升5.04%报12.08美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2605742942","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605742942?lang=zh_cn&edition=full","pubTime":"2026-01-22 23:13","pubTimestamp":1769094782,"startTime":"0","endTime":"0","summary":"北京时间2026年01月22日23时13分，Emergent Biosolutions Inc.股票出现异动，股价大幅上涨5.04%。截至发稿，该股报12.08美元/股，成交量9.7464万股，换手率0.19%，振幅4.43%。Emergent Biosolutions Inc.股票所在的制药行业中，整体涨幅为0.72%。其相关个股中，脑再生科技、Shuttle Pharmaceuticals Holdings, Inc.、Scilex Holding Company涨幅较大，Shuttle Pharmaceuticals Holdings, Inc.、Akanda Corp.、Inmed Pharmaceuticals Inc.较为活跃，换手率分别为27.62%、6.90%、1.72%，振幅较大的相关个股有脑再生科技、Shuttle Pharmaceuticals Holdings, Inc.、Apimeds Pharmaceuticals Us, Inc.，振幅分别为46.51%、26.96%、13.09%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260122231303a44a7841&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260122231303a44a7841&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["EBS","BK4583","BK4139"],"gpt_icon":0},{"id":"1163083735","title":"Emergent BioSolutions获FDA批准Narcan®鼻喷雾剂新包装补充申请 便携式包装盒提升纳洛酮日常急救可及性","url":"https://stock-news.laohu8.com/highlight/detail?id=1163083735","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163083735?lang=zh_cn&edition=full","pubTime":"2026-01-14 21:04","pubTimestamp":1768395877,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已批准Emergent BioSolutions提交的Narcan®鼻喷雾剂补充新药申请。该批准允许这款救命药物纳洛酮采用新型便携式包装盒，显著提升其在日常应急场景中的可及性。\n新型携带式包装设计旨在简化取用流程，使非专业人员在紧急情况下能快速实施用药。作为阿片类药物过量逆转的关键救治手段，纳洛酮的可及性提升将有效强化社区急救网络建设。\n此次监管突破标志着 Emergent BioSolutions 在扩大公共健康安全防护范围方面取得重要进展。通过优化药品包装的便携性与识别度，企业进一步践行其提升紧急医疗产品可及性的核心使命。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EBS","BK4139","BK4583"],"gpt_icon":0},{"id":"2603680932","title":"Emergent Biosolutions Inc.盘中异动 大幅下跌5.38%报12.26美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603680932","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603680932?lang=zh_cn&edition=full","pubTime":"2026-01-12 22:33","pubTimestamp":1768228386,"startTime":"0","endTime":"0","summary":"北京时间2026年01月12日22时33分，Emergent Biosolutions Inc.股票出现波动，股价急速下挫5.38%。截至发稿，该股报12.26美元/股，成交量23.3056万股，换手率0.44%，振幅9.94%。Emergent Biosolutions Inc.股票所在的制药行业中，整体涨幅为0.17%。其相关个股中，Bioage Labs, Inc.、Akanda Corp.、Ani Pharmaceuticals, Inc.涨幅较大，Akanda Corp.、苏轩堂、Painreform Ltd.较为活跃，换手率分别为218.29%、38.19%、3.04%，振幅较大的相关个股有Emergent Biosolutions Inc.、Akanda Corp.、苏轩堂，振幅分别为9.94%、6.13%、5.96%。Emergent Biosolutions Inc.公司简介：Emergent BioSolutions Inc 为政府和医疗保健提供商提供公共卫生产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112223307a7120561&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112223307a7120561&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4583","EBS"],"gpt_icon":0},{"id":"1133582145","title":"Emergent BioSolutions宣布偿还1亿美元定期贷款本金，迈向多年转型战略的重要里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1133582145","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133582145?lang=zh_cn&edition=full","pubTime":"2026-01-12 20:32","pubTimestamp":1768221133,"startTime":"0","endTime":"0","summary":"Emergent BioSolutions于近日宣布完成对定期贷款本金1亿美元的偿付计划，这一举措标志着该公司在其制定的多年转型道路上取得了实质性突破。此次债务结构的优化不仅有效减轻了企业财务负担，更展现出管理层对战略重组的坚定执行力。\n通过主动削减债务规模，企业得以释放更多现金流用于核心业务聚焦与技术升级，为长期可持续发展奠定坚实基础。这一财务决策与公司此前公布的转型蓝图高度契合，彰显出其通过资本结构优化驱动业务蜕变的清晰路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4583","EBS"],"gpt_icon":0},{"id":"1173193947","title":"Emergent BioSolutions获美国战争部2150万美元订单，将于2026年供应炭疽疫苗","url":"https://stock-news.laohu8.com/highlight/detail?id=1173193947","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173193947?lang=zh_cn&edition=full","pubTime":"2026-01-09 05:32","pubTimestamp":1767907940,"startTime":"0","endTime":"0","summary":"Emergent BioSolutions Inc (EBS) 宣布获得美国战争部一份价值2150万美元的订单，为其供应炭疽疫苗Biothrax，预计交付时间为2026年。该订单进一步巩固了公司在生物防御领域的市场地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EBS","BK4583"],"gpt_icon":0},{"id":"1182283796","title":"Emergent BioSolutions与Panther达成协议 支持非洲CDC主导的Mpox研究在非洲持续开展","url":"https://stock-news.laohu8.com/highlight/detail?id=1182283796","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182283796?lang=zh_cn&edition=full","pubTime":"2026-01-08 21:05","pubTimestamp":1767877534,"startTime":"0","endTime":"0","summary":"Emergent BioSolutions与Panther公司共同宣布，双方已签署一项合作协议，旨在为非洲疾病控制与预防中心（Africa CDC）主导的Mpox病毒研究项目在非洲大陆的持续推进提供支持。该合作将强化区域公共卫生应对能力，助力传染病防控研究体系的完善。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4583","EBS"],"gpt_icon":0},{"id":"1176907510","title":"Emergent BioSolutions获得美国FDA批准，在加拿大温尼伯生产Raxibacumab药品","url":"https://stock-news.laohu8.com/highlight/detail?id=1176907510","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176907510?lang=zh_cn&edition=full","pubTime":"2025-12-12 21:30","pubTimestamp":1765546223,"startTime":"0","endTime":"0","summary":"Emergent BioSolutions获得美国FDA批准，在其位于加拿大温尼伯的生产基地制造Raxibacumab药品。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EBS","BK4583"],"gpt_icon":0},{"id":"2586778235","title":"芝商所部分恢复正常运作 外汇交易平台EBS市场重启","url":"https://stock-news.laohu8.com/highlight/detail?id=2586778235","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586778235?lang=zh_cn&edition=full","pubTime":"2025-11-28 20:27","pubTimestamp":1764332852,"startTime":"0","endTime":"0","summary":"经历数小时系统故障导致全球市场受扰后，芝商所开始逐步恢复正常运作。根据芝商所集团官网公告，外汇交易平台EBS市场已于伦敦时间中午12点重启。此次故障影响了这个全球性交易平台，追踪标普500指数、道琼斯工业平均指数和纳斯达克100指数的数百万份合约，几乎每天24小时都在芝商所进行交易。正值部分头寸仓位需要从一个月度合约延展到另一个月度合约的这个关键时刻，市场参与者损失了数小时交易时间，此次故障引发广泛不满。据设施运营商CyrusOne称，此次故障是由芝加哥地区某数据中心的冷却系统问题引发的。\n\n美股频道更多独家策划、专家专栏，免费查阅>>\n\r\n            责任编辑：山上","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"27eb7f263c6d927c789c3113b6570403","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2025/11/28202754472324.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["EBS","BK4139","BK4583"],"gpt_icon":0},{"id":"2586601784","title":"芝商所 EBS 市场将于 20:00 开放","url":"https://stock-news.laohu8.com/highlight/detail?id=2586601784","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586601784?lang=zh_cn&edition=full","pubTime":"2025-11-28 19:59","pubTimestamp":1764331154,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，据金十报道，芝商所（CME）表示，EBS 市场将于格林威治标准时间 12:00（北京时间 20:00）开放。 ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2224684","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EBS","BK4583"],"gpt_icon":0},{"id":"2585199088","title":"Emergent Biosolutions Inc.盘中异动 股价大跌5.16%报9.38美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2585199088","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585199088?lang=zh_cn&edition=full","pubTime":"2025-11-21 01:12","pubTimestamp":1763658766,"startTime":"0","endTime":"0","summary":"北京时间2025年11月21日01时12分，Emergent Biosolutions Inc.股票出现波动，股价急速下跌5.16%。截至发稿，该股报9.38美元/股，成交量41.0862万股，换手率0.78%，振幅8.13%。Emergent Biosolutions Inc.股票所在的制药行业中，整体跌幅为0.40%。其相关个股中，Scilex Holding Company、Therapeuticsmd, Inc.、Scynexis, Inc.涨幅较大，Inmed Pharmaceuticals Inc.、Akanda Corp.、Hims & Hers Health, Inc.较为活跃，换手率分别为242.90%、6.61%、5.71%，振幅较大的相关个股有Therapeuticsmd, Inc.、Scilex Holding Company、Sunshine Biopharma Inc C/Wts ，振幅分别为29.70%、22.41%、21.25%。Emergent Biosolutions Inc.公司简介：Emergent BioSolutions Inc 为政府和医疗保健提供商提供公共卫生产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251121011246a4afb55f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251121011246a4afb55f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["EBS","BK4139","BK4583"],"gpt_icon":0},{"id":"1122366777","title":"Emergent BioSolutions庆祝Narcan®鼻用喷雾剂获得美国FDA批准10周年，并重申增加纳洛酮获取渠道的承诺","url":"https://stock-news.laohu8.com/highlight/detail?id=1122366777","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122366777?lang=zh_cn&edition=full","pubTime":"2025-11-18 21:01","pubTimestamp":1763470871,"startTime":"0","endTime":"0","summary":"Emergent BioSolutions庆祝Narcan®鼻用喷雾剂获得美国FDA批准10周年，并重申增加纳洛酮获取渠道的承诺","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EBS","BK4583"],"gpt_icon":0},{"id":"2571532268","title":"瑞立科密深交所上市：募资19亿 首日上涨50% 公司市值114亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2571532268","media":"雷递网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571532268?lang=zh_cn&edition=full","pubTime":"2025-09-30 23:34","pubTimestamp":1759246449,"startTime":"0","endTime":"0","summary":"广州瑞立科密汽车电子股份有限公司（简称：“瑞立科密”，证券代码：001285）今日在深交所主板上市。瑞立科密发行股票4,504.4546万股，发行价为42.28元，募资19亿元。","market":"hk","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20250930/6389487198561680597949182.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20250930/6389487198561680597949182.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n31350/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["EBS","BK4139","BK4583"],"gpt_icon":0},{"id":"1167003072","title":"Emergent Biosolutions获得1700万美元合同修订 用于天花抗病毒药物Tembexa®口服悬浮液并加强美国供应链","url":"https://stock-news.laohu8.com/highlight/detail?id=1167003072","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167003072?lang=zh_cn&edition=full","pubTime":"2025-09-15 20:37","pubTimestamp":1757939836,"startTime":"0","endTime":"0","summary":"Emergent Biosolutions获得1700万美元合同修订，用于口服悬浮液Tembexa®（Brincidofovir）天花抗病毒药物，并加强美国整体供应链。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","EBS","BK4139"],"gpt_icon":0},{"id":"2566228938","title":"机动车主动安全系统相关核心部件厂商瑞立科密(001285.SZ)拟首次公开发行4504.45万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2566228938","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566228938?lang=zh_cn&edition=full","pubTime":"2025-09-11 06:43","pubTimestamp":1757544188,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞立科密 披露招股意向书，公司拟首次公开发行4504.4546万股，初始战略配售发行数量为450.4454万股。初步询价日期2025年9月15日，申购日期2025年9月19日。公告称，公司是专业从事机动车主动安全系统相关核心部件研发、生产和销售的国家高新技术企业，主营业务为机动车主动安全系统和铝合金精密压铸件的研发、生产和销售以及技术服务。自2022年度至2024年度，归属于母公司所有者的净利润为9696.47万元、2.36亿元、2.69亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1343882.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","EBS","BK4583"],"gpt_icon":0},{"id":"1148748705","title":"Emergent Biosolutions获得3000万美元合同修订，用于两剂炭疽疫苗Cyfendus®（炭疽疫苗吸附佐剂型）的暴露后预防用途","url":"https://stock-news.laohu8.com/highlight/detail?id=1148748705","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148748705?lang=zh_cn&edition=full","pubTime":"2025-09-02 19:40","pubTimestamp":1756813221,"startTime":"0","endTime":"0","summary":"Emergent Biosolutions获得3000万美元合同修订，用于两剂炭疽疫苗Cyfendus®（炭疽疫苗吸附佐剂型）的暴露后预防用途","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4583","EBS"],"gpt_icon":0},{"id":"2518822412","title":"Emergent Biosolutions Inc.盘中异动 早盘快速下跌5.20%报5.47美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518822412","media":"市场透视","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518822412?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:35","pubTimestamp":1741613729,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时35分，Emergent Biosolutions Inc.股票出现波动，股价大幅跳水5.20%。截至发稿，该股报5.47美元/股，成交量5.3544万股，换手率0.10%，振幅1.56%。Emergent Biosolutions Inc.股票所在的制药行业中，整体跌幅为0.64%。其相关个股中，Sonoma Pharmaceuticals, Inc.、Alpha Teknova, Inc.、Flora Growth Corp.涨幅较大，Sonoma Pharmaceuticals, Inc.、Petros Pharmaceuticals, Inc.、苏轩堂较为活跃，换手率分别为52.14%、8.77%、2.85%，振幅较大的相关个股有Shuttle Pharmaceuticals Holdings, Inc.、惠普森医药、Alpha Teknova, Inc.，振幅分别为13.84%、12.67%、12.14%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213529a26a2645&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213529a26a2645&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4583","EBS","BK4139"],"gpt_icon":0},{"id":"2516677553","title":"Emergent Biosolutions Inc.股价重挫15.96% 市值跌4963.83万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516677553","media":"市场透视","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516677553?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:32","pubTimestamp":1741098779,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时32分，Emergent Biosolutions Inc.股票出现异动，股价快速下跌15.96%。截至发稿，该股报5.74美元/股，成交量35.3898万股，换手率0.65%，振幅4.39%。Emergent Biosolutions Inc.股票所在的制药行业中，整体跌幅为0.02%。Emergent Biosolutions Inc.公司简介：Emergent BioSolutions Inc 向政府和医疗保健提供者提供公共卫生产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223259abe7f004&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223259abe7f004&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4583","EBS"],"gpt_icon":0},{"id":"2516966912","title":"Emergent BioSolutions(EBS.US)：2024年Q4财报实现营收1.947亿美元，前值为2.766亿美元，预期值为2.547亿美元；每股收益为0.05美元，前值为-0.77美元，预期值为-0.50美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516966912","media":"金融界","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516966912?lang=zh_cn&edition=full","pubTime":"2025-03-04 05:32","pubTimestamp":1741037576,"startTime":"0","endTime":"0","summary":"Emergent BioSolutions(EBS.US)：2024年Q4财报实现营收1.947亿美元，前值为2.766亿美元，预期值为2.547亿美元；每股收益为0.05美元，前值为-0.77美元，预期值为-0.50美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/04053248499197.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["EBS"],"gpt_icon":0},{"id":"1101283831","title":"Emergent BioSolutions第四季度调整后每股收益$0.05，超出预期$(0.49)，销售额$194.70M不及预期$254.67M","url":"https://stock-news.laohu8.com/highlight/detail?id=1101283831","media":"财报速递","labels":["merge","express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101283831?lang=zh_cn&edition=full","pubTime":"2025-03-04 05:31","pubTimestamp":1741037470,"startTime":"0","endTime":"0","summary":"Emergent BioSolutions报告的季度每股收益为$0.05，比分析师预期的$高出110.2%。公司报告的季度销售额为$194.70M，不及分析师预期的$254.67M，低23.55%。这比去年同期的销售额$276.60M减少了29.61%。以上内容来自Benzinga Earnings专栏，原文如下：Emergent BioSolutions  reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $ by 110.2 percent. This is a 106.49 percent increase over losses of $ per share from the same period last year.  The company reported quarterly sales of $194.70 million which missed the analyst consensus estimate of $254.67 mi","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Emergent BioSolutions第四季度调整后每股收益$0.05，超出预期$(0.49)，销售额$194.70M不及预期$254.67M","news_tag":"merge,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EBS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.emergentbiosolutions.com","stockEarnings":[{"period":"1week","weight":-0.0308},{"period":"1month","weight":-0.0264},{"period":"3month","weight":0.0819},{"period":"6month","weight":0.1481},{"period":"1year","weight":0.1008},{"period":"ytd","weight":-0.1343}],"compareEarnings":[{"period":"1week","weight":-0.0134},{"period":"1month","weight":-0.0127},{"period":"3month","weight":0.0305},{"period":"6month","weight":0.0744},{"period":"1year","weight":0.12},{"period":"ytd","weight":0.0014}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Emergent Biosolutions Inc.于1998年5月在美国密歇根州成立，随后在 2004年6月改为特拉华公司。公司拥有两个经营部门：生物防卫和生物科学。该公司是一家全球性生命科学公司，专注于提供创新的准备和响应解决方案，以应对意外、故意和自然发生的公共健康威胁。","yearOnYearQuotes":[{"month":1,"riseRate":0.7,"avgChangeRate":0.042008},{"month":2,"riseRate":0.4,"avgChangeRate":-0.002947},{"month":3,"riseRate":0.421053,"avgChangeRate":-0.035402},{"month":4,"riseRate":0.473684,"avgChangeRate":-0.035609},{"month":5,"riseRate":0.578947,"avgChangeRate":0.111206},{"month":6,"riseRate":0.631579,"avgChangeRate":0.011895},{"month":7,"riseRate":0.578947,"avgChangeRate":0.106316},{"month":8,"riseRate":0.473684,"avgChangeRate":-0.017792},{"month":9,"riseRate":0.368421,"avgChangeRate":-0.034511},{"month":10,"riseRate":0.578947,"avgChangeRate":0.029583},{"month":11,"riseRate":0.578947,"avgChangeRate":-0.002144},{"month":12,"riseRate":0.6,"avgChangeRate":0.044099}],"exchange":"NYSE","name":"Emergent Biosolutions","nameEN":"Emergent BioSolutions"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Emergent Biosolutions(EBS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Emergent Biosolutions(EBS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Emergent Biosolutions,EBS,Emergent Biosolutions股票,Emergent Biosolutions股票老虎,Emergent Biosolutions股票老虎国际,Emergent Biosolutions行情,Emergent Biosolutions股票行情,Emergent Biosolutions股价,Emergent Biosolutions股市,Emergent Biosolutions股票价格,Emergent Biosolutions股票交易,Emergent Biosolutions股票购买,Emergent Biosolutions股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Emergent Biosolutions(EBS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Emergent Biosolutions(EBS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}